J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 1730KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 92(9): 1234-1236, 1991

Report on the annual meeting

LAK CELL ADOPTIVE IMMUNOTHERAPY AND ITS PROBLEMS

Department of Surgery, Research lnstitute for Nuclear Medicine and Biology, Hiroshima University, Hiroshima, Japan

Yoshiyuki Yamaguchi, Takahiro Takayama, Hiroyuki Kawami, Yukio Sato, Nobutoshi Baba, Katsumasa Kuroi, Tetsuya Toge

Clinical efficacy of lymphokine-activated killer (LAK) cell adoptive immunotherapy (AIT) in combination with plasma exchange and interluekin (IL-2) was investigated in 24 patients with advanced cancer. Partial response (PR) was found in 4 patients (20%), including 1 primary liver tumor, 1 metastatic lung tumor from renal cancer and 2 malignant pleural effusions from gastric and lung cancer. Based on these results, new AIT in combination with plasma exchange, OK-432, IL2 and cyclophosphamide was designed to target liver and lung tumors, in which LAK cells and other drugs were administered through the catheter located in the feeding artery of the tumor. Out of ten patients treated, 1 (10%) with metastatic liver tumor from gallbladder cancer was evaluated as PR.
It is suggested that a strategy to enhance tumor accumulation and recognition of LAK cells should be attempted for development of gastrointestinal cancer therapy with AIT.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.